|
1
|
Wang Y and Deng B: Hepatocellular
carcinoma: Molecular mechanism, targeted therapy, and biomarkers.
Cancer Metastasis Rev. Feb 2–2023.(Epub ahead of print). View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang JD, Hainaut P, Gores GJ, Amadou A,
Plymoth A and Roberts LR: A global view of hepatocellular
carcinoma: Trends, risk, prevention and management. Nat Rev
Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards
R, Qin W and Wang C: Evolving therapeutic landscape of advanced
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bagchi S, Yuan R and Engleman EG: Immune
checkpoint inhibitors for the treatment of cancer: Clinical impact
and mechanisms of response and resistance. Annu Rev Pathol.
16:223–249. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naimi A, Mohammed RN, Raji A, Chupradit S,
Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S,
Shomali N, et al: Tumor immunotherapies by immune checkpoint
inhibitors (ICIs); the pros and cons. Cell Commun Signal.
20:442022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yap TA, Parkes EE, Peng W, Moyers JT,
Curran MA and Tawbi HA: Development of immunotherapy combination
strategies in cancer. Cancer Discov. 11:1368–1397. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bote H, Mesas A, Baena J, Herrera M and
Paz-Ares L: Emerging immune checkpoint inhibitors for the treatment
of non-small cell lung cancer. Expert Opin Emerg Drugs. 27:289–300.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jácome AA, Castro ACG, Vasconcelos JPS,
Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF,
Gil RA, et al: Efficacy and safety associated with immune
checkpoint inhibitors in unresectable hepatocellular carcinoma: A
meta-analysis. JAMA Netw Open. 4:e21361282021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng Y, Wang S, Cai J, Ke A and Fan J:
The progress of immune checkpoint therapy in primary liver cancer.
Biochim Biophys Acta Rev Cancer. 1876:1886382021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai J, Liang P, Li Q, Feng R and Liu J:
Cancer immunotherapy-immune checkpoint inhibitors in hepatocellular
carcinoma. Recent Pat Anticancer Drug Discov. 16:239–248. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Finn RS, Ryoo BY, Merle P, Kudo M,
Bouattour M, Lim HY, Breder VV, Edeline J, Chao Y, Ogasawara S, et
al: Results of KEYNOTE-240: Phase 3 study of pembrolizumab (Pembro)
vs best supportive care (BSC) for second line therapy in advanced
hepatocellular carcinoma (HCC). J Clin Oncol. 37 (15
Suppl):S40042019. View Article : Google Scholar
|
|
15
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Doroshow DB, Bhalla S, Beasley MB, Sholl
LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS and Hirsch FR:
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Nat Rev Clin Oncol. 18:345–362. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rizzo A, Ricci AD and Brandi G: PD-L1,
TMB, MSI, and other predictors of response to immune checkpoint
inhibitors in biliary tract cancer. Cancers (Basel). 13:5582021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Valero C, Lee M, Hoen D, Weiss K, Kelly
DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, et al:
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden
as biomarkers of tumor response to immune checkpoint inhibitors.
Nat Commun. 12:7292021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei J, Feng J, Weng Y, Xu Z, Jin Y, Wang
P, Cui X, Ruan P, Luo R, Li N and Peng M: The prognostic value of
ctDNA and bTMB on immune checkpoint inhibitors in human cancer.
Front Oncol. 11:7069102021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nabet BY, Esfahani MS, Moding EJ, Hamilton
EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, et
al: Noninvasive early identification of therapeutic benefit from
immune checkpoint inhibition. Cell. 183:363–376.e13. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alwarawrah Y, Kiernan K and MacIver NJ:
Changes in nutritional status impact immune cell metabolism and
function. Front Immunol. 9:10552018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia H, Zhang W, Zheng Q, Zhang Y, Mu X,
Wei C, Wang X and Liu Y: Predictive value of the prognostic
nutritional index in advanced non-small cell lung cancer patients
treated with immune checkpoint inhibitors: A systematic review and
meta-analysis. Heliyon. 9:e174002023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ni L, Huang J, Ding J, Kou J, Shao T, Li
J, Gao L, Zheng W and Wu Z: Prognostic nutritional index predicts
response and prognosis in cancer patients treated with immune
checkpoint inhibitors: A systematic review and meta-analysis. Front
Nutr. 9:8230872022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian BW, Yang YF, Yang CC, Yan LJ, Ding
ZN, Liu H, Xue JS, Dong ZR, Chen ZQ, Hong JG, et al: Systemic
immune-inflammation index predicts prognosis of cancer
immunotherapy: Systemic review and meta-analysis. Immunotherapy.
14:1481–1496. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kou J, Huang J, Li J, Wu Z and Ni L:
Systemic immune-inflammation index predicts prognosis and
responsiveness to immunotherapy in cancer patients: A systematic
review and meta-analysis. Clin Exp Med. Mar 26–2023.(Epub ahead of
print). View Article : Google Scholar
|
|
26
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Colombo M and Sangiovanni A: Treatment of
hepatocellular carcinoma: Beyond international guidelines. Liver
Int. 35 (Suppl 1):S129–S138. 2015. View Article : Google Scholar
|
|
29
|
Chonprasertsuk S and Vilaichone RK:
Epidemiology and treatment of hepatocellular carcinoma in Thailand.
Jpn J Clin Oncol. 47:294–297. 2017.PubMed/NCBI
|
|
30
|
Huang J, Zhang Y, Peng Z, Gao H, Xu L,
Jiao LR and Chen M: A modified TNM-7 staging system to better
predict the survival in patients with hepatocellular carcinoma
after hepatectomy. J Cancer Res Clin Oncol. 139:1709–1719. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xing R, Gao J, Cui Q and Wang Q:
Strategies to improve the antitumor effect of immunotherapy for
hepatocellular carcinoma. Front Immunol. 12:7832362021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsilimigras DI, Bagante F, Sahara K, Moris
D, Hyer JM, Wu L, Ratti F, Marques HP, Soubrane O, Paredes AZ, et
al: Prognosis after resection of barcelona clinic liver cancer
(BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive
assessment of the current BCLC classification. Ann Surg Oncol.
26:3693–3700. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Y, Hu H, Yuan X, Fan X and Zhang C:
Advances in immune checkpoint inhibitors for advanced
hepatocellular carcinoma. Front Immunol. 13:8967522022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Wang Y, Gao P and Ding J: Immune
checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer
Lett. 555:2160382023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schoenfeld AJ and Hellmann MD: Acquired
resistance to immune checkpoint inhibitors. Cancer Cell.
37:443–455. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li N, Hou X, Huang S, Tai R, Lei L, Li S,
Abuliz A, Wang G and Yang S: Biomarkers related to immune
checkpoint inhibitors therapy. Biomed Pharmacother. 147:1124702022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung immune
prognostic index with immune checkpoint inhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun H, Chen L, Huang R, Pan H, Zuo Y, Zhao
R, Xue Y and Song H: Prognostic nutritional index for predicting
the clinical outcomes of patients with gastric cancer who received
immune checkpoint inhibitors. Front Nutr. 9:10381182022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haas M, Lein A, Fuereder T, Brkic FF,
Schnoell J, Liu DT, Kadletz-Wanke L, Heiduschka G and Jank BJ: The
geriatric nutritional risk index (GNRI) as a prognostic biomarker
for immune checkpoint inhibitor response in recurrent and/or
metastatic head and neck cancer. Nutrients. 15:8802023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y and Ni Q: Prognostic and
clinicopathological significance of systemic immune-inflammation
index in cancer patients receiving immune checkpoint inhibitors: A
meta-analysis. Ann Med. 55:808–819. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee JH, Hyung S, Lee J and Choi SH:
Visceral adiposity and systemic inflammation in the obesity paradox
in patients with unresectable or metastatic melanoma undergoing
immune checkpoint inhibitor therapy: A retrospective cohort study.
J Immunother Cancer. 10:e0052262022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sonehara K, Tateishi K, Araki T, Komatsu
M, Yamamoto H and Hanaoka M: Prognostic value of the geriatric
nutritional risk index among patients with previously treated
advanced non-small cell lung cancer who subsequently underwent
immunotherapy. Thorac Cancer. 12:1366–1372. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shoji F, Takeoka H, Kozuma Y, Toyokawa G,
Yamazaki K, Ichiki M and Takeo S: Pretreatment prognostic
nutritional index as a novel biomarker in non-small cell lung
cancer patients treated with immune checkpoint inhibitors. Lung
Cancer. 136:45–51. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ren B, Shen J, Qian Y and Zhou T:
Sarcopenia as a determinant of the efficacy of immune checkpoint
inhibitors in non-small cell lung cancer: A meta-analysis. Nutr
Cancer. 75:685–695. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stühler V, Herrmann L, Rausch S, Stenzl A
and Bedke J: Role of the systemic immune-inflammation index in
patients with metastatic renal cell carcinoma treated with
first-line ipilimumab plus nivolumab. Cancers (Basel). 14:29722022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qi WX, Xiang Y, Zhao S and Chen J:
Assessment of systematic inflammatory and nutritional indexes in
extensive-stage small-cell lung cancer treated with first-line
chemotherapy and atezolizumab. Cancer Immunol Immunother.
70:3199–3206. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mountzios G, Samantas E, Senghas K, Zervas
E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et
al: Association of the advanced lung cancer inflammation index
(ALI) with immune checkpoint inhibitor efficacy in patients with
advanced non-small-cell lung cancer. ESMO Open. 6:1002542021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang X, Wang D, Sun T, Li W and Dang C:
Advanced lung cancer inflammation index (ALI) predicts prognosis of
patients with gastric cancer after surgical resection. BMC Cancer.
22:6842022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Barth DA, Brenner C, Riedl JM, Prinz F,
Klocker EV, Schlick K, Kornprat P, Lackner K, Stöger H, Stotz M, et
al: External validation of the prognostic relevance of the advanced
lung cancer inflammation index (ALI) in pancreatic cancer patients.
Cancer Med. 9:5473–5479. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pian G, Hong SY and Oh SY: Prognostic
value of advanced lung cancer inflammation index in patients with
colorectal cancer liver metastases undergoing surgery. Tumori.
108:56–62. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xiong B, Fu B, Wu Y, Gao F and Hou C: Body
composition predicts prognosis of hepatocellular carcinoma patients
undergoing immune checkpoint inhibitors. J Cancer Res Clin Oncol.
Jul 4–2023.(Epub ahead of print). View Article : Google Scholar
|
|
52
|
Zhu HF, Feng JK, Xiang YJ, Wang K, Zhou
LP, Liu ZH, Cheng YQ, Shi J, Guo WX and Cheng SQ: Combination of
alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict
treatment response and survival outcomes of patients with
unresectable hepatocellular carcinoma treated with immune
checkpoint inhibitors. BMC Cancer. 23:5472023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang L, Feng J, Kuang T, Chai D, Qiu Z,
Deng W, Dong K, Zhao K and Wang W: Blood biomarkers predict
outcomes in patients with hepatocellular carcinoma treated with
immune checkpoint Inhibitors: A pooled analysis of 44 retrospective
sudies. Int Immunopharmacol. 118:1100192023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo
Y, Zhang L, Xue Y, Song H and Li X: Controlling nutritional status
(CONUT) predicts survival in gastric cancer patients with immune
checkpoint inhibitor (PD-1/PD-L1) outcomes. Front Pharmacol.
13:8369582022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
van de Donk PP, Kist de Ruijter L, Lub-de
Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RS,
de Groot DJA and de Vries EG: Molecular imaging biomarkers for
immune checkpoint inhibitor therapy. Theranostics. 10:1708–1718.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Collins N and Belkaid Y: Control of
immunity via nutritional interventions. Immunity. 55:210–223. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Di Giosia P, Stamerra CA, Giorgini P,
Jamialahamdi T, Butler AE and Sahebkar A: The role of nutrition in
inflammaging. Ageing Res Rev. 77:1015962022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Childs CE, Calder PC and Miles EA: Diet
and immune function. Nutrients. 11:19332019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Swarbrick GM, Gela A, Cansler ME, Null MD,
Duncan RB, Nemes E, Shey M, Nsereko M, Mayanja-Kizza H, Kiguli S,
et al: Postnatal expansion, maturation, and functionality of MR1T
cells in humans. Front Immunol. 11:5566952020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Divangahi M, Aaby P, Khader SA, Barreiro
LB, Bekkering S, Chavakis T, van Crevel R, Curtis N, DiNardo AR,
Dominguez-Andres J, et al: Trained immunity, tolerance, priming and
differentiation: Distinct immunological processes. Nat Immunol.
22:2–6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Barrea L, Di Somma C, Muscogiuri G,
Tarantino G, Tenore GC, Orio F, Colao A and Savastano S: Nutrition,
inflammation and liver-spleen axis. Crit Rev Food Sci Nutr.
58:3141–3158. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Iddir M, Brito A, Dingeo G, Fernandez Del
Campo SSF, Samouda H, La Frano MR and Bohn T: Strengthening the
immune system and reducing inflammation and oxidative stress
through diet and nutrition: Considerations during the COVID-19
crisis. Nutrients. 12:15622020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dong J, Zhang W, Zhang T, Chen X, Zhao J,
Zeng Y, Chen Y, Wei X, Lei T, Wang P, et al: Baseline nutritional
status could be a predictor for radiation esophagitis in esophageal
cancer patients undergoing radiotherapy. Ann Transl Med.
8:11482020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kaymak Cerkesli ZA, Ozkan EE and Ozseven
A: The esophageal dose-volume parameters for predicting Grade I–II
acute esophagitis correlated with weight loss and serum albumin
decrease in lung cancer radiotherapy. J Cancer Res Ther. 17:94–98.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zheng C, Liu S, Feng J and Zhao X:
Prognostic value of inflammation biomarkers for survival of
patients with neuroblastoma. Cancer Manag Res. 12:2415–2425. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Golovtchenko AM and Raichvarg D:
Lymphocytes. Roles in cellular immunity and humoral immunity. Ann
Biol Clin (Paris). 33:63–74. 1975.(In French). PubMed/NCBI
|
|
67
|
Cancro MP and Tomayko MM: Memory B cells
and plasma cells: The differentiative continuum of humoral
immunity. Immunol Rev. 303:72–82. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Papayannopoulos V: Neutrophil
extracellular traps in immunity and disease. Nat Rev Immunol.
18:134–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Quail DF, Amulic B, Aziz M, Barnes BJ,
Eruslanov E, Fridlender ZG, Goodridge HS, Granot Z, Hidalgo A,
Huttenlocher A, et al: Neutrophil phenotypes and functions in
cancer: A consensus statement. J Exp Med. 219:e202200112022.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Junqueira C, Crespo Â, Ranjbar S, de
Lacerda LB, Lewandrowski M, Ingber J, Parry B, Ravid S, Clark S,
Schrimpf MR, et al: FcγR-mediated SARS-CoV-2 infection of monocytes
activates inflammation. Nature. 606:576–584. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kapellos TS, Bonaguro L, Gemünd I, Reusch
N, Saglam A, Hinkley ER and Schultze JL: Human monocyte subsets and
phenotypes in major chronic inflammatory diseases. Front Immunol.
10:20352019. View Article : Google Scholar : PubMed/NCBI
|
